Medivir has announced the launch of Adasuve inhaled loxapine for the treatment of agitation in schizophrenic or bipolar patients in Sweden, Norway, Finland, and Denmark. Medivir acquired the rights to commercialize Adasuve in all five Nordic countries from Grupo Ferrer in September 2013.
Medivir Executive VP, Commercial, Henrik Krook, commented, “It is gratifying to be able to launch Adasuve in the four main Nordic countries as a complement to our existing product portfolio.”
Grupo Ferrer acquired European, CIS, and Latin American rights to the product from Alexza Pharmaceuticals in 2011. Teva is marketing Adasuve in the US.
Read the Medivir press release.
